Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers-Reference-Cited by-同舟云学术

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

Published:2021-01-21 Issue:2 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Patel Eshan U.¹²^ORCID,Bloch Evan M.¹,Clarke William¹,Hsieh Yu-Hsiang³,Boon Denali⁴,Eby Yolanda¹,Fernandez Reinaldo E.⁵,Baker Owen R.⁶,Keruly Morgan⁵,Kirby Charles S.¹,Klock Ethan⁵,Littlefield Kirsten⁷,Miller Jernelle¹,Schmidt Haley A.¹,Sullivan Philip¹,Piwowar-Manning Estelle¹,Shrestha Ruchee¹,Redd Andrew D.⁵⁶,Rothman Richard E.³,Sullivan David⁷,Shoham Shmuel⁵,Casadevall Arturo⁷^ORCID,Quinn Thomas C.⁵⁶,Pekosz Andrew⁷^ORCID,Tobian Aaron A. R.¹⁵,Laeyendecker Oliver⁵⁶^ORCID

Affiliation:

1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

3. Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

4. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

5. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

6. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA

7. Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Abstract

Accurate serological assays to detect antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 infection and identify potential candidates for coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) donation. This study compared the performances of commercial enzyme immunoassays (EIAs) with respect to detection of IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAbs). The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) for detection of IgG or total antibodies to SARS-CoV-2 was evaluated using cross-sectional samples from potential CCP donors who had prior molecular confirmation of SARS-CoV-2 infection ( n = 214) and samples from prepandemic emergency department patients without SARS-CoV-2 infection ( n = 1,099).

Funder

HHS | National Institutes of Health

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute on Drug Abuse

U.S. Department of Defense

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

HHS | NIH | National Heart, Lung, and Blood Institute

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link